Pharming Group (NASDAQ:PHAR - Get Free Report) traded up 10.1% during mid-day trading on Friday . The stock traded as high as $10.60 and last traded at $11.03. 907 shares changed hands during trading, a decline of 86% from the average session volume of 6,421 shares. The stock had previously closed at $10.02.
Analyst Ratings Changes
Several analysts recently commented on the company. Oppenheimer raised their target price on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 20th.
Read Our Latest Stock Report on PHAR
Pharming Group Stock Performance
The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The firm has a market cap of $789.77 million, a price-to-earnings ratio of -44.65 and a beta of -0.08. The company has a fifty day moving average price of $9.00 and a two-hundred day moving average price of $8.92.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. As a group, equities research analysts expect that Pharming Group will post -0.2 EPS for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
